Company intelligence / Profile preview

Polbionica

Warsaw, Mazowieckie, Polandpolbionica.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Polbionica has developed the world’s first fully vascularized bionic pancreas using proprietary bioinks and bioprinting technology. Their preclinical results show safety in animal studies. The company aims to move into clinical trials to demonstrate efficacy in humans. They also provide advanced materials and devices supporting broader applications in tissue engineering and drug development.[1][2][5]

Therapeutic areas: GastroenterologyEndocrinologyOncology
Modalities: 3D bioprinted organs (notably pancreas)Bioinks for tissue engineering and organ printingStem cell-derived therapies (future plans)Organoid models for drug testing
Industry: Biotech

Partnerships

Funded by Polish National Center for Research and Development via STRATEGMED programcollaborations with academic experts/KOLs

Beyond the preview

Go deeper on Polbionica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polbionica.

Explore the full profile